With 2.38 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.2 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $7.1 whereas the lowest price it dropped to was $6.18. The 52-week range on GLTO shows that it touched its highest point at $21.06 and its lowest point at $3.76 during that stretch. It currently has a 1-year price target of $8.00. Beta for the stock currently stands at 0.92.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GLTO was up-trending over the past week, with a rise of 64.22%, but this was up by 48.56% over a month. Three-month performance surged to 39.87% while six-month performance fell -51.45%. The stock lost -66.03% in the past year, while it has gained 44.09% so far this year. A look at the trailing 12-month EPS for GLTO yields -18.59 with Next year EPS estimates of -19.47. EPS is expected to decline by -17.40% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 14.83%.
Float and Shares Shorts:
At present, 1.32 million GLTO shares are outstanding with a float of 1.14 million shares on hand for trading. On 2025-02-28, short shares totaled 18343.0, which was 139.0 higher than short shares on 1738281600. In addition to Dr. Hans T. Schambye M.D., Ph.D. as the firm’s Co-Founder, President, CEO & Director, Mr. Garrett Winslow Esq. serves as its Senior VP, General Counsel & Corporate Secretary.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, GLTO reported revenue of $0.0 and operating income of -$7102000.0. The EBITDA in the recently reported quarter was -$7227000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GLTO since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With GLTO analysts setting a high price target of 10.0 and a low target of 6.0, the average target price over the next 12 months is 8.0. Based on these targets, GLTO could surge 49.25% to reach the target high and fall by -10.45% to reach the target low. Reaching the average price target will result in a growth of 19.4% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$15.91 being high and -$15.91 being low. For GLTO, this leads to a yearly average estimate of -$15.91. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
